Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model
- 678 Downloads
Hypoxia-inducible factor 1α (HIF-1α) activity is one of the major players in hypoxia-mediated glioma progression and resistance to therapies, and therefore the focus of this study was the evaluation of HIF-1α modulation in relation to tumour response with the purpose of identifying imaging biomarkers able to document tumour response to treatment in a murine glioma model.
U251-HRE-mCherry cells expressing Luciferase under the control of a hypoxia responsive element (HRE) and mCherry under the control of a constitutive promoter were used to assess HIF-1α activity and cell survival after treatment, both in vitro and in vivo, by optical, MRI and positron emission tomography imaging.
This cell model can be used to monitor HIF-1α activity after treatment with different drugs modulating transduction pathways involved in its regulation. After temozolomide (TMZ) treatment, HIF-1α activity is early reduced, preceding cell cytotoxicity. Optical imaging allowed monitoring of this process in vivo, and carbonic anhydrase IX (CAIX) expression was identified as a translatable non-invasive biomarker with potential clinical significance. A preliminary in vitro evaluation showed that reduction of HIF-1α activity after TMZ treatment was comparable to the effect of an Hsp90 inhibitor, opening the way for further elucidation of its mechanism of action.
The results of this study suggest that the U251-HRE-mCherry cell model can be used for the monitoring of HIF-1α activity through luciferase and CAIX expression. These cells can become a useful tool for the assessment and improvement of new targeted tracers for potential theranostic procedures.
KeywordsTemozolomide HIF-1alpha Optical imaging Biomarker CAIX
Raccagni I. was supported by a fellowship from the Doctorate in Biomedical Technologies, Department of Health Sciences, University of Milan-Bicocca, Milan, Italy. The authors wish to thank Dr. S. Todde for production and control quality of radiotracers. The authors thank Fondazione IRCCS Ca’ Granda for allowing the use of the imaging system IVIS Spectrum/CT. This work was supported in part by FP7 funded INSERT project (HEALTH-2012-INNOVATION-1, GA305311) and by Fondazione IRCCS Ca’ Granda - Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi” (INGM) grant in Molecular Medicine (2013 edition).
Conflicts of interest
- 3.Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004;64(19):6845–8.CrossRefPubMedGoogle Scholar
- 4.Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60(6):1541–5.PubMedGoogle Scholar
- 21.Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7(7):1851–63.CrossRefPubMedGoogle Scholar
- 25.A phase I/II study of BEZ235 in patients with advanced solid malignancies enriched by patients with advanced breast cancer. ClinicalTrial.gov Identifier number: NCT00620594.Google Scholar
- 26.Efficacy and safety of the combination therapy of dabrafenib and trametinib in subjects with BRAF V600E- mutated rare cancers. ClinicalTrial.gov Identifier number: NCT02034110.Google Scholar
- 33.Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989–1000.Google Scholar
- 48.Lau J, Zhang Z, Hundal-Jabal N, Liu Z, Benard F, Lin KS. Synthesis and evaluation of monomeric, dimeric and trimeric benzenesulfonamide derivatives for imaging carbonic anhydrase IX with PET. J Nucl Med 2014;55(Suppl 1):444.Google Scholar
- 49.Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996;19(3):184–91.CrossRefPubMedGoogle Scholar
- 54.Yamaki H, Nakajima M, Seimiya H, Saya H, Sugita M, Tsuruo TJ. Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. J Antibiot 1995;48(9):1021–6.CrossRefPubMedGoogle Scholar